Literature DB >> 11574895

Major depression: prevalence, treatment utilization and age in Canada.

S B Patten1, B Sedmak, M L Russell.   

Abstract

OBJECTIVE: To determine the relationships between age, prevalence of major depression and antidepressant treatment in Canadian populations by using data from three health surveys.
BACKGROUND: Major depression is an important disorder, and there is a concern that treatment for it may be underutilized. Age may have an impact on treatment use.
METHODS: Two of the surveys incorporated into the present analysis were random digit dial telephone surveys, with sample sizes of 2542 subjects and 796 subjects, respectively. The third data source was the National Population Health Survey (n=73,402), which used some face to face and some telephone-based data collection methods. In each of these studies, major depression was evaluated using a short form version of the Composite International Diagnostic Interview for Major Depression. Diagnostic status was evaluated in relation to current use of antidepressant medications, age and other relevant factors. All analyses accounted for unequal selection probabilities and clustering inherent in the sampling procedures.
RESULTS: The prevalence of major depression was consistently found to be highest in subjects under the age of 45 years. However, older subjects were more likely to report having depression diagnosed. Antidepressant treatment was found to be less frequent in young subjects, despite these subjects being in the group with the highest prevalence of depression. Younger respondents were less likely to see a physician about their depressive symptoms, and when they did they were less likely to be told that they had a depressive disorder.
CONCLUSIONS: The data presented indicate that antidepressant medications tend to be used less frequently in younger than older age groups in Canada. Additional studies are needed to confirm optimal use rates in relation to age.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574895

Source DB:  PubMed          Journal:  Can J Clin Pharmacol        ISSN: 1198-581X


  6 in total

1.  Antidepressant utilization in Canada.

Authors:  Cynthia A Beck; Scott B Patten; Jeanne V A Williams; Jian Li Wang; Shawn R Currie; Colleen J Maxwell; Nady El-Guebaly
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-10       Impact factor: 4.328

2.  Under-diagnosis of mood disorders in Canada.

Authors:  L Pelletier; S O'Donnell; J Dykxhoorn; L McRae; S B Patten
Journal:  Epidemiol Psychiatr Sci       Date:  2016-05-06       Impact factor: 6.892

3.  Use of medication and psychological counselling among Canadians with mood and/or anxiety disorders.

Authors:  Siobhan O'Donnell; Maria Syoufi; Wayne Jones; Kathryn Bennett; Louise Pelletier
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-05       Impact factor: 3.240

4.  Serotonin transporter modulation in blood lymphocytes from patients with major depression.

Authors:  Lucimey Lima; Mary Urbina
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

5.  Prevalence and association of depression in in-patient orthopaedic trauma patients: A single centre study in India.

Authors:  Santosh Kumar; Vikas Verma; Umesh Kushwaha; Emilie J Calvello Hynes; Amit Arya; Abhishek Agarwal
Journal:  J Clin Orthop Trauma       Date:  2019-12-19

Review 6.  Sadness as an integral part of depression.

Authors:  Sabine Mouchet-Mages; Franck J Baylé
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.